Adam West, Eli Lilly and Company

Adam West Adam West leads the Informatics Capabilities organization in Research IT at Eli Lilly and Company. He’s responsible for a group of 20 PhD and Master’s level individuals with a diverse set of backgrounds including biology, machine learning, and computer science. His group is tasked to support robust analysis, facilitate discovery research, sharing of data and tools, foster collaboration, and remove limitations of scale and technical complexity. The group has responsibilities for Next-Generation Sequencing (NGS), computer methods development, software and data engineering, and analytics with a focus on informatics. Recent projects include Omics Data Infrastucture development (ODIN), Auto-immune human transcriptome array development and analysis, cell-line and PDX model support and analysis, RNASeq and Whole Exome Sequencing (WES) pipeline development, cancer immuno-biology biomarker workflow, external intelligence and natural-language process, diabetes patient journey social listening, and assay support for proteomics and 2D cell imaging.

In his 22 years with Lilly IT, Adam has worked in US Demand and Market Research, Lilly Research Labs, and Clincial Development. In those areas, Adam lead the development of tailoring systems for genomic assays in clinical outcomes, PK/PD and adverse events to support hypothesis generation and exploration of study results. He also constructed a genomic management system integrating biological tools and external NCBI data sources. He also built a large scale data warehouse system for the analysis of prescribing habits of physicians across the US. Prior to Lilly, Adam worked with an environmental research company where he constructed a laboratory information managemenet systems (LIMS), instrument automation, logistics tracking systems and system administration for UNIX/Oracle systems.

Adam attended Indiana University/Purduce University (IUPUI) in the field of Computer Science. He left the univserity to start a small software development and game company that has since produced several computer and hobby board games, working with manufactuers, distributors and publishers throughout the world. Adam and his wife Ellen have three daughters who are attending local universities.

Selected Publications and Invited Talks

Guo Y, Jolly RA, Halstead BW, Baker TK, Stutz JP, Huffman M, Calley JN, West A, Gao H, Searfoss GH, Li S, Irizarry AR, Qian HR, Stevens JL, Ryan TP. Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes. Toxicol Sci. 2007 Apr;96(2):294-309. Epub 2007 Jan 25.

West A. XML, RDF, OWL and LSID: Ontology integration within evolving 'omic' standards, Invited Talk International Oracle Life Sciences and Healthcare User Group Meeting, Boston, MA, 2006

Amar Kumar; McAhren, S.M.; West, A.; Hong Gao; Higgins, M.A.; Halstead, B.W.; Searfoss, G.H.; Caliey, J.N.; Ryan, T.P.; Dow, E.R. Abstracting genes to gene ontology terms allows comparison across multiple species. Systems Engineering, 2005. ICSEng 2005.

Dow E.R.; et al, Gene Ontology Term Enrichment from Microarray Studies Using a Hyperbolic Viewer Facilitates Comparison Between Experiment Groups, ISMB, 2005

Sessions

10:05 AM - 10:35 AM

AI Applications for Identifying New Drug Candidates

Your CEO knows the company needs to adopt AI/ML technology, but they don't want to get involved in the details.  You now have the budget, but you need to produce an ROI.  What are your options when it comes to using AI tools to identify new drug candidates?  AI has the potential to become an indispensable tool but only if the near-term ROI is realized.  What questions do you need to ask to get this right and make a difference in speed, cost and outcomes?

Moderator

Speakers

  • Adam West

    Adam West Director, Research Data Sciences and Engineering Eli Lilly and Company


Download Latest Agenda